KSQ Therapeutics
The company is deploying CRISPRomics for novel drug development across broad therapeutic areas and is currently advancing a proprietary pipeline of tumor- and immune-focused drug candidates. Learn more
Launch date
Employees
Market cap
-
Enterprise valuation
€291—436m (Dealroom.co estimates Sep 2018.)
Cambridge Massachusetts (HQ)
Authorizing premium user...